drugset
drugset / Trial / NCT02365948

A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects

NCT02365948 ↗

Phase 1 Completed 36 enrolled UCB Pharma Parexel · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will characterize the pharmacokinetics (PK) of certolizumab pegol (CZP) and evaluate safety of CZP in healthy Chinese subjects. 36 subjects will be randomized to receive one of 3 dose levels of CZP or placebo. The total study duration will be approximately 71-94 days for each subject.

Timeline

Start
2015-03
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic 100 mg Subcutaneous
Subject Certolizumab Pegol Protein / enzyme biologic 200 mg Subcutaneous
Subject Certolizumab Pegol Protein / enzyme biologic 400 mg Subcutaneous

Indications

No indication recorded.